2\textsuperscript{nd} Meeting on detecting and responding to outbreaks of HIV among PWID

Update on country situation: Lithuania

Lisbon, 12\textsuperscript{th} October 201
Epidemiological update

HIV notifications in PWID

<table>
<thead>
<tr>
<th></th>
<th>Jan</th>
<th>Feb</th>
<th>Mar</th>
<th>Apr</th>
<th>May</th>
<th>Jun</th>
<th>Jul</th>
<th>Aug</th>
<th>Total reported Jan to Sept 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of HIV cases in total</strong></td>
<td>2</td>
<td>5</td>
<td>8</td>
<td>11</td>
<td>32</td>
<td>19</td>
<td>13</td>
<td>12</td>
<td>102</td>
</tr>
<tr>
<td><strong>Number of HIV in PWID</strong></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>17</td>
<td>7</td>
<td>6</td>
<td>4</td>
<td>43</td>
</tr>
</tbody>
</table>


Comments: Data source: Centre for Communicable Diseases and AIDS at the Ministry of Health of the Republic of Lithuania. Data is from National HIV/AIDS database.
Epidemiological update (2011)

Proportion: HIV in IDU / all cases HIV
- overall, and if available: 51.8% (86/166) by mode of transmission
- 5/86 in young PWID (<25)
- in new PWID (injecting < 2 years) not available
- other breakdown if relevant (e.g. stimulant injectors, gender, in OST…) not available

Proportion: HVC in IDU / all cases HVC
- overall, and if available: 4/43 (acute HVC)
- 3/4 in young PWID (<25)
- in new PWID (injecting < 2 years) not available
- other breakdown if relevant (e.g. stimulant injectors, gender, in OST…) not available
Behavioural surveillance

• Not available for 2010-2011
• Data will be available in 2013 January (new data collecting system are introduced)
## PWID population size estimates

<table>
<thead>
<tr>
<th>Population size estimates in:</th>
<th>PWID (Local)</th>
<th>PWID (National)</th>
<th>PDUs</th>
<th>PDUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number:</td>
<td>3200</td>
<td>-</td>
<td>4300</td>
<td>~ 6000</td>
</tr>
<tr>
<td>Year:</td>
<td>2006</td>
<td>-</td>
<td>2006</td>
<td>2007</td>
</tr>
<tr>
<td>Source:</td>
<td>Estimation was carried out by Dr. Gordon Hay, as part of the UNODC Project HIV/AIDS prevention and care among injecting drug users (IDUs) and in prison settings in Estonia, Latvia and Lithuania, in 2007</td>
<td>-</td>
<td>Estimation was carried out by Dr. Gordon Hay, as part of the UNODC Project HIV/AIDS prevention and care among injecting drug users (IDUs) and in prison settings in Estonia, Latvia and Lithuania, in 2007</td>
<td>Estimation was carried out by Audrone Astrauskiene, Valerij Dobrovolskij and Rimantas Stukas</td>
</tr>
</tbody>
</table>
Interventions

Coverage
- % of estimated POUs in opioid substitution treatment No data
- % of POUs / PWID reporting OST in last 4 weeks No data
- Number of syringes distributed per estimated PWID per year 45
- Number of syringes PWID report they obtained for personal use No data
- % tested for HIV in the last 12 months (excluding known positives) No data

Policies
- National Program on HIV/AIDS/STI Prevention and Control 2010-2012

Service provision
- As of January 1, 2011, substitution treatment was applied in 19 units.
  11 harm reduction services, 5 regional Drug dependent centers
Self-assessing preventive intervention situation (I)

<table>
<thead>
<tr>
<th>Key Intervention ECDC / EMCDDA</th>
<th>Implemented? (Yes/No/partly)</th>
<th>STRENGTH</th>
<th>WEAKNESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>INJECTION EQUIPMENT Provision and legal access</td>
<td>Yes</td>
<td>11 harm reduction services</td>
<td>Not enough coverage in all country regions</td>
</tr>
<tr>
<td>VACCINATION HBV, HAV, tetanus etc.</td>
<td>Yes</td>
<td>HBV - Infants and 12 years old children are vaccinated</td>
<td>No targetted action programs on hepatitis for injection drug users HAV – voluntary vaccination, not for free</td>
</tr>
<tr>
<td>DRUG DEPENDENCE TREATMENT – OST etc</td>
<td>Yes</td>
<td>Free treatment All drug dependent patience are insured by National Health Insurance Fund (OST are compensated by NHIF)</td>
<td></td>
</tr>
<tr>
<td>TESTING HIV, HCV, HBV, TB etc</td>
<td>Partly</td>
<td>National MON order on HIV testing exist</td>
<td>Lack of financial resources for hepatitis testing</td>
</tr>
<tr>
<td>INFECTIOUS DISEASE TREATMENT HIV, HCV, HBV, TB etc</td>
<td>Yes</td>
<td>Treatment are available for all who needed according National treatment algorithms</td>
<td>IDUs adherence of treatment</td>
</tr>
</tbody>
</table>
## Self-assessing preventive intervention situation (II)

<table>
<thead>
<tr>
<th>Key Intervention ECDC/EMCDDA</th>
<th>Implemented? (Yes/No/partly)</th>
<th>STRENGTH</th>
<th>WEAKNESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEALTH PROMOTION safer injecting behaviour; sexual health etc</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TARGETED DELIVERY OF SERVICES organised and delivered according to user needs and local conditions</td>
<td>Partly</td>
<td>Mobile clinics</td>
<td>Not enough coverage in all country regions</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lack of political commitment in municipality level</td>
</tr>
<tr>
<td>IMPLEMENTED IN COMBINATION?</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Prevention funding

How did prevention funding change between 2009 to 2012?

1) for HIV: Increase □  No Change ■ Decrease □
2) for PWID: Increase □  No Change ■ Decrease □

Do you anticipate reductions in funding for HIV prevention among PWID in the coming 2 years?
- No

What are the main funding sources for prevention programmes?
- National budget
Drug markets

Are there any changes in heroin availability in your country?

- Increase □
- No Change ■
- Decrease □

Are there any evidence of “new” drugs entering the market, especially methamphetamines? (based on seizure data and/or qualitative data)

- No

Is there an observed change in injecting stimulant use?

- Increase □
- No Change ■
- Decrease □
Main challenges

**Surveillance and monitoring:**
- “refresh” sentinel surveillance system in country
- assess number of IDU

**Harm reduction:**
- lack of political commitment in municipality level

**Drug treatment for PWID:**
- to enlarge drug dependents treatment

**Collaboration between public health and drug authorities:**
- improve collaboration between public health and decision makers to insure better coordination and service provision
Thank you!